Molecular Biomarkers in Cardiac Hypertrophy

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2019 Jan 17

PMID 30648807

Citations 33

Authors

Liu Zhu

Chao Li

Qiang Liu

Weiting Xu

Xiang Zhou

Affiliations

Soon will be listed here.

Abstract

Cardiac hypertrophy is characterized by an increase in myocyte size in the absence of cell division. This condition is thought to be an adaptive response to cardiac wall stress resulting from the enhanced cardiac afterload. The pathogenesis of heart dysfunction, which is one of the primary causes of morbidity and mortality in elderly people, is often associated with myocardial remodelling caused by cardiac hypertrophy. In order to well understand the potential mechanisms, we described the molecules involved in the development and progression of myocardial hypertrophy. Increasing evidence has indicated that micro-RNAs are involved in the pathogenesis of cardiac hypertrophy. In addition, molecular biomarkers including vascular endothelial growth factor B, NAD-dependent deacetylase sirtuin-3, growth/differentiation factor 15 and glycoprotein 130, also play important roles in the development of myocardial hypertrophy. Knowing the regulatory mechanisms of these biomarkers in the heart may help identify new molecular targets for the treatment of cardiac hypertrophy.

Citing Articles

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.

Aman A, Akram A, Akram B, Maham M, Bokhari M, Akram A Open Heart. 2025; 12(1).

PMID: 39988344 PMC: 11848667. DOI: 10.1136/openhrt-2025-003215.

Role of EZH2-mediated abnormal histone H3K27me3 methylation in pressure overload-induced cardiac remodeling in mice.

Ma Y, Peng C, Wu S, Tian X Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025; 49(9):1390-1399.

PMID: 39931769 PMC: 11814386. DOI: 10.11817/j.issn.1672-7347.2024.230335.

A Thorough Navigation of miRNA's Blueprint in Crafting Cardiovascular Fate.

Nazir A, Uwishema O, Shariff S, Franco W, El Masri N, Ayele N Health Sci Rep. 2024; 7(11):e70136.

PMID: 39502130 PMC: 11535861. DOI: 10.1002/hsr2.70136.

Identification of immune-related genes and small-molecule drugs in hypertension-induced left ventricular hypertrophy based on machine learning algorithms and molecular docking.

Zhou M, Li T, Lv S, Gan W, Zhang F, Che Y Front Immunol. 2024; 15:1351945.

PMID: 38994368 PMC: 11236603. DOI: 10.3389/fimmu.2024.1351945.

The crucial relationship between miRNA-27 and CSE/HS, and the mechanism of action of GLP-1 in myocardial hypertrophy.

Gao S, Li Y, Liu M, Xiong X, Cui C, Huo Q Int J Med Sci. 2024; 21(5):965-977.

PMID: 38616996 PMC: 11008482. DOI: 10.7150/ijms.93720.

References

Lang D . Cardiac hypertrophy and oxidative stress: a leap of faith or stark reality?. Heart. 2002; 87(4):316-7. PMC: 1767053. DOI: 10.1136/heart.87.4.316. View

Sun X, Zhang C . MicroRNA-96 promotes myocardial hypertrophy by targeting mTOR. Int J Clin Exp Pathol. 2016; 8(11):14500-6. PMC: 4713555. View

Zhu L, Li C, Liu Q, Xu W, Zhou X . Molecular biomarkers in cardiac hypertrophy. J Cell Mol Med. 2019; 23(3):1671-1677. PMC: 6378174. DOI: 10.1111/jcmm.14129. View

Pan W, Zhong Y, Cheng C, Liu B, Wang L, Li A . MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS One. 2013; 8(1):e53950. PMC: 3541228. DOI: 10.1371/journal.pone.0053950. View

Hagberg C, Mehlem A, Falkevall A, Muhl L, Fam B, Ortsater H . Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature. 2012; 490(7420):426-30. DOI: 10.1038/nature11464. View

Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T . Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol. 1992; 148(12):4066-71. View

Molkentin J, Dorn 2nd G . Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63:391-426. DOI: 10.1146/annurev.physiol.63.1.391. View

Guo R, Hu N, Kandadi M, Ren J . Facilitated ethanol metabolism promotes cardiomyocyte contractile dysfunction through autophagy in murine hearts. Autophagy. 2012; 8(4):593-608. PMC: 3405837. DOI: 10.4161/auto.18997. View

Zaragosi L, Wdziekonski B, Le Brigand K, Villageois P, Mari B, Waldmann R . Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol. 2011; 12(7):R64. PMC: 3218826. DOI: 10.1186/gb-2011-12-7-r64. View

10.

Zhang R, Khoo M, Wu Y, Yang Y, Grueter C, Ni G . Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11(4):409-17. DOI: 10.1038/nm1215. View

11.

Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y . Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008; 377(1):114-9. DOI: 10.1016/j.bbrc.2008.09.086. View

12.

Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B . Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009; 30(19):2346-53. DOI: 10.1093/eurheartj/ehp261. View

13.

Lin J, Lwin T, Zhao J, Tam W, Choi Y, Moscinski L . Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2010; 25(1):145-52. PMC: 3083119. DOI: 10.1038/leu.2010.230. View

14.

Zhang W, Qian P, Zhang X, Zhang M, Wang H, Wu M . Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. J Biol Chem. 2015; 290(22):13812-29. PMC: 4447958. DOI: 10.1074/jbc.M115.653261. View

15.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

16.

Zhong W, Yang J, Cao Q, Huan X . Association between miR-181b and PKG 1 in myocardial hypertrophy and its clinical implications. Exp Ther Med. 2015; 10(3):857-862. PMC: 4533127. DOI: 10.3892/etm.2015.2647. View

17.

Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M . Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem. 1999; 274(30):21217-22. DOI: 10.1074/jbc.274.30.21217. View

18.

Anderson M . Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther. 2005; 106(1):39-55. DOI: 10.1016/j.pharmthera.2004.11.002. View

19.

Ryan D, Oliveira-Fernandes M, Lavker R . MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. Mol Vis. 2006; 12:1175-84. View

20.

Khan S, Ng K, Dhillon O, Kelly D, Quinn P, Squire I . Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009; 30(9):1057-65. DOI: 10.1093/eurheartj/ehn600. View